J&J stays focused on early-stage deals; Ionis bags a milestone from GSK;

@FierceBiotech: Biden maps out a 'moonshot' approach to cancer with plans to 'break down silos' in R&D. More | Follow @FierceBiotech

@JohnCFierce: FDA slaps down BioMarin's Duchenne's drug as rival nears a moment of truth. News | Follow @JohnCFierce

@DamianFierce: "I made a point to talk to female guests," he said. More from Bloomberg | Follow @DamianFierce

> Bloomberg reports that J&J ($JNJ) chief Alex Gorsky plans to continue a strategy of acquiring early-stage treatments rather than switch to a megamerger approach. Story

> Ionis Pharmaceuticals, formerly Isis, has earned a $1.5 million milestone from GlaxoSmithKline after launching a Phase I study of the hep B drug IONIS-HBV-LRx. Release

Medical Device News

@FierceMedDev: Medical device sales reps scouting out new jobs in 2016: Report. More | Follow @FierceMedDev

@EmilyWFierce: Olympus, FDA implicated in Senate probe of duodenoscope devices. Report | Follow @EmilyWFierce

> Hospira pump business nears chopping block as Pfizer mulls potential sale: Bloomberg. More

> FDA makes increasing use of 'real-world' device data a strategic priority. Report

> JPM: Boston Sci updates on Watchman reimbursement, Synergy launch. Article

Pharma News

@FiercePharma: U.S.-based Certara creates drug developing consultancy in China. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: J&J will boost workforce at South Africa consumer meds plant after $18M upgrade. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce:   head Slaoui says the company's vax and  businesses need each other--aka, no break-up, please. Article | Follow @CarlyHFierce

> For its next pare-down move, Pfizer weighs sale of Hospira pump business: Bloomberg. More

> FTC stats show pharma backing off pay-for-delay deals after SCOTUS ruling. Report

> Pfizer expands consumer biz in China with Treerly supplements buy. Article

Pharma Manufacturing News

> U.K.'s Oxford BioMedica gets MHRA nod for new manufacturing facility. Item

> GSK turns to K+N for supplier logistics. News

> FDA finds issues with Walgreens' infusion compounding services. Report

> EMA says Spain has taken action against drugmaker for shortcomings. Story

> Bayer opens large China plant for traditional Chinese and Western OTC meds. Article

CRO News

> Evotec hits an R&D milestone with J&J in an ambitious Alzheimer's collaboration. News

> Eurofins buys Dutch drug-testing firm to pad its services. More

> AMRI signs a trio of deals in R&D, manufacturing and marketing. Report

> Catalent inks a $619M deal to help Roche develop targeted therapies. Article

Pharma Asia News

> China-focused CASI Pharmaceuticals gets Marqbio review by CFDA. Item

> China continues to find problems in drug production. Article

> In Japan, fast approvals, more R&D cash and price cuts ahead. Report

> Astellas, Medivation report successful enzalutamide mCRPC PhII data in Lancet. More

> Cipla says top 50 drugs in development could bring in $30B. Story

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.